[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342054-105":59,"doc-detail-342054-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multivariable-prognostic-modelling-to-improve-prediction-of-colorectal-cancer-recurrence-the-prospect-trial","Multivariable prognostic modelling to improve prediction of colorectal cancer recurrence - the PROSPeCT trial","","Improving prognostication to direct personalised therapy remains an unmet need. This multicentre trial prospectively investigated CT imaging, genetic, and immunohistochemical markers to improve prediction of colorectal cancer recurrence. Patients with primary disease underwent CT staging, then follow-up identified recurrence and death. A baseline 3-year clinicopathological model was built from pre-specified variables and compared with models adding CT perfusion, RAS/RAF and DNA mismatch repair, plus angiogenesis and hypoxia markers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multivariable-prognostic-modelling-to-improve-prediction-of-colorectal-cancer-recurrence-the-prospect-trial/342054/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multivariable-prognostic-modelling-to-improve-prediction-of-colorectal-cancer-recurrence-the-prospect-trial/342054.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the PROSPeCT trial?","Question",{"text":112,"@type":113},"To improve prediction of colorectal cancer recurrence so personalised therapy can be better directed, by prospectively evaluating CT, genetic, and immunohistochemical markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study build and compare the prognostic models?",{"text":117,"@type":113},"It developed a baseline 3-year clinicopathological model from pre-specified variables, then tested whether adding CT perfusion, genetic markers (RAS/RAF and DNA mismatch repair), and immunohistochemical angiogenesis/hypoxia markers improved prediction beyond tumour-node staging.",{"name":119,"@type":110,"acceptedAnswer":120},"Did adding the CT, genetic, and immunohistochemical markers improve recurrence prediction?",{"text":121,"@type":113},"No. The addition of prespecified CT perfusion, genetic, and immunohistochemical markers did not improve prediction beyond the clinicopathological model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342054,1790865692,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Goh et al. European Radiology (2024) 34:6992–7001  \n[https://doi.org/10.1007/s00330-024-10803-7](https://doi.org/10.1007/s00330-024-10803-7)  \nGASTROINTESTINAL Open Access  \nMultivariable prognostic modelling to improve prediction of colorectal cancer recurrence: the PROSPeCT trial  \nVicky Goh 1,2* , Susan Mallett3, Victor Boulter4, Robert Glynne-Jones5, Saif Khan6, Sarah Lessels7,  \nDominic Patel6, Davide Prezzi 1,2, Manuel Rodriguez-Justo6, Stuart A. Taylor3, Richard Beable8, Margaret Betts9, David J. Breen 10, Ingrid Britton 11, John Brush 12, Peter Correa 13, Nicholas Dodds 14, Joanna Dunlop7,  \nSoﬁa Gourtsoyianni1, Nyree Grifﬁn2, Antony Higginson8, Andrew Lowe 15, Andrew Slater9, Madeline Strugnell 16, Damian Tolan 17, Ian Zealley 18 and Steve Halligan3, For PROSPECT investigators  \nAbstract  \nObjective Improving prognostication to direct personalised therapy remains an unmet need. This study prospectively investigated promising CT, genetic, and immunohistochemical markers to improve the prediction of colorectal cancer recurrence.  \nMaterial and methods This multicentre trial (ISRCTN 95037515) recruited patients with primary colorectal cancer undergoing CT staging from 13 hospitals. Follow-up identiﬁed cancer recurrence and death. A baseline model for cancer recurrence at 3 years was developed from pre-speciﬁed clinicopathological variables (age, sex, tumour-node stage, tumour size, location, extramural venous invasion, and treatment). Then, CT perfusion (blood ﬂow, blood volume, transit time and permeability), genetic (RAS, RAF, and DNA mismatch repair), and immunohistochemical markers of angiogenesis and hypoxia (CD105, vascular endothelial growth factor, glucose transporter protein, and hypoxia-inducible factor) were added to assess whether prediction improved over tumour-node staging alone as the main outcome measure.  \nResults Three hundred twenty-six of 448 participants formed the ﬁnal cohort (226 male; mean 66± 10 years. 227 (70%) had ≥ T3 stage cancers; 151 (46%) were node-positive; 81 (25%) developed subsequent recurrence. The sensitivity and speciﬁcity of staging alone for recurrence were 0.56 [95% CI: 0.44, 0.67] and 0.58 [0.51, 0.64], respectively. The baseline clinicopathologic model improved speciﬁcity (0.74 [0.68, 0.79], with equivalent sensitivity of 0.57 [0.45, 0.68] for high vs medium/low-risk participants. The addition of prespeciﬁed CT perfusion, genetic, and immunohistochemical markers did not improve prediction over and above the clinicopathologic model (sensitivity, 0.58–0.68; speciﬁcity, 0.75–0. 76).  \nConclusion A multivariable clinicopathological model outperformed staging in identifying patients at high risk of recurrence. Promising CT, genetic, and immunohistochemical markers investigated did not further improve prognostication in rigorous prospective evaluation.  \nClinical relevance statement A prognostic model based on clinicopathological variables including age, sex, tumour-node stage, size, location, and extramural venous invasion better identiﬁes colorectal cancer patients at high risk of recurrence for neoadjuvant/adjuvant therapy than stage alone.  \nA list of authors and their afﬁliations appears at the end of the paper.  \n*Correspondence: Vicky Goh  \n[vicky.goh@kcl.ac. uk](vicky.goh@kcl.ac. uk)  \nFull list of author information is available at the end of the article.  \n© The Author(s) 2024 . Open Access This article is licensed under a Creative Commons Attribution 4 . 0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence ","cbCaisaZ4geg1vcw","https://ap.wps.com/l/cbCaisaZ4geg1vcw","pdf",1530616,"English","# Key Points\n# Abstract\n## Objective\n## Material and methods\n## Results\n## Conclusion\n## Clinical relevance statement\n# Introduction","[{\"question\":\"What was the main objective of the PROSPeCT trial?\",\"answer\":\"To improve prediction of colorectal cancer recurrence so personalised therapy can be better directed, by prospectively evaluating CT, genetic, and immunohistochemical markers.\"},{\"question\":\"How did the study build and compare the prognostic models?\",\"answer\":\"It developed a baseline 3-year clinicopathological model from pre-specified variables, then tested whether adding CT perfusion, genetic markers (RAS/RAF and DNA mismatch repair), and immunohistochemical angiogenesis/hypoxia markers improved prediction beyond tumour-node staging.\"},{\"question\":\"Did adding the CT, genetic, and immunohistochemical markers improve recurrence prediction?\",\"answer\":\"No. The addition of prespecified CT perfusion, genetic, and immunohistochemical markers did not improve prediction beyond the clinicopathological model.\"}]","Multivariable prognostic modelling to improve prediction of colorectal cancer recurrence - the PROSPeCT trial | PDF",1790044920,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acb66e375221332219400122551707f7.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08e2ab758513bdd006675aa4b29920db.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0140bcfe577f0f808e29c7d6d0cde0d.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcbc7b32f24890905710d14ff3419028.webp",980,1301]